01At a glance
02What it is
Permanent neonatal diabetes due to KCNJ11 mutations is a gain-of-function channelopathy: an overactive ATP-sensitive potassium channel suppresses insulin secretion. The striking clinical result is that most patients can be switched from insulin injections to oral sulfonylurea tablets, which close the channel and restore insulin — a channel-blocker cure, not a degrader or replacement.
03What goes wrong
Gain-of-function ion channel. Activating KCNJ11 mutations prevent the ATP-sensitive potassium (KATP) channel from closing, keeping the pancreatic beta-cell hyperpolarized and suppressing insulin secretion. This causes neonatal diabetes. The toxic species is a hyperactive channel, NOT an accumulating protein.
04How NIGHTINGALE routes it
Recommended modality: channel_blocker (sulfonylurea — closes the KATP channel, restoring insulin secretion)
NOT eligible. The disease is a gain-of-function ION CHANNEL, not a toxic aggregate. The correct modality is a channel BLOCKER (sulfonylurea) that closes the hyperactive KATP channel and restores insulin secretion — not protein degradation.
05Treatment today
Glibenclamide (glyburide) — sulfonylurea
Long-established (off-label for neonatal diabetes; NEJM 2006 demonstrated the switch)Sulfonylureas bind and close the KATP channel, depolarizing the beta-cell and restoring insulin secretion. Most patients with KCNJ11 neonatal diabetes can be switched from insulin to oral sulfonylureas, often with better glycemic control.
06In the pipeline
- No degrader or gene therapy indicated — the channel blocker is the definitive approach
Key reference: PMID 32027066 · PubMed
07Verification
Every line below is the registry's own verification record — what was checked, against which source, and what is still open.
- uniprot: Q14654 = KCNJ11 (Kir6.2), 390 aa — VERIFIED via UniProt REST API (live)
- gene mutation: Activating KCNJ11 mutations (gain-of-function) — VERIFIED (OMIM 606176; NEJM 2006)
- inheritance: Autosomal dominant — VERIFIED (OMIM 606176)
- orpha code: 224 = Neonatal diabetes mellitus (Active) — VERIFIED via Orphanet API (live, 2026-07-02)
- drug mw: Glibenclamide 494.0 Da, CID 3488 — commonly cited (not re-verified this session)
- fda date: Sulfonylureas long-established; off-label for neonatal diabetes — N/A
08Sources
| Fact | Source | Accession | Retrieved |
|---|---|---|---|
| Gene/protein identity | UniProt | Q14654 (KCNJ11, 390 aa) | 2026-10-04 |
| Disease classification & definition | Orphanet | ORPHAcode 224 (Neonatal diabetes mellitus) | 2026-10-04 |
| Inheritance & genetics | OMIM | 606176 (Diabetes Mellitus, Permanent Neonatal) | 2026-10-04 |
| Sulfonylurea switch (mechanism evidence) | NEJM 2006 | Switching from Insulin to Oral Sulfonylureas (Pearson et al., NEJM 355:467) | 2026-10-04 |
Corrections carried into registry v2 (2)
- VERIFIED (2026-10-04): built fresh. ORPHAcode 224 confirmed live via Orphanet API.
- CLARIFIED: KCNJ11 neonatal diabetes is a GAIN-OF-FUNCTION CHANNEL — the correct modality is a channel BLOCKER (sulfonylurea), NOT a degrader, NOT enzyme replacement, NOT gene therapy.